Category: Flu Vaccine

Page 3«..2345..1020..»

Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza – BioSpace

July 28, 2024

TORONTO, July 26, 2024 /CNW/ - The National Advisory Committee on Immunizations (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 continues to recommend Fluzone High-Dose Quadrivalent among the preferential influenza vaccines, over standard dose influenza vaccines, to protect adults 65 years of age and older against influenza. According to NACI, Fluzone High-Dose Quadrivalent has the most substantial body of supporting evidence among preferentially recommended vaccines for adults 65 years of age and older.i

Delphine Lansac

General Manager, Vaccines Canada, Sanofi

More than one out of two seniors in Canada who received a flu shot were immunized with Fluzone High-Dose this past flu season. Fluzone High-Dose has a longstanding and consistent body of clinical evidence supporting its benefits to protect adults 65 years and older from influenza and reduce the risk of its potentially severe complications. As a leader in public health protection in Canada, with roots dating back 110 years, we are proud to soon be manufacturing Fluzone High-Dose right here in Toronto.

Dr. Angel Chu MD, FRCPC

In the newest NACI statement, Fluzone High-Dose continues to be recommended for adults 65 years of age and older. NACI also recognizes Fluzone High-Dose has the most substantial body of supporting evidence among flu vaccines for seniors.

Influenza can cause mild to severe illness, including approximately 12,000 hospitalizations and 3,500 deaths annually in Canadaii. Some populations, especially young children and adults 65 years of age and older, are at a higher risk for serious influenza complicationsiii. Vaccination is the most effective way to prevent influenza and its complicationsiv.

Fluzone High-Dose Quadrivalent Influenza Vaccine is specifically designed to provide protection for adults 65 years of age and older with 4 times the active component dosage of a standard vaccine. To date, Fluzone High-Dose is available in more than 20 countries including the US, Canada, and Germany and continues to be publicly funded in Canada by numerous provinces and territories.

Fluzone High-Dose Quadrivalent Influenza Vaccine will transition to a trivalent formulation for the 2025-2026 influenza season. The timing of this transition is also in line with the recommendation of European health authorities. This is following the direction of the World Health Organization to exclude the B/Yamagata lineage from influenza vaccine formulations due to the absence of confirmed detection of naturally occurring B/Yamagata lineage viruses since March 2020. The benefits of annual influenza vaccination remain unchanged, whether trivalent or quadrivalent. There are no safety issues associated with the continued use of quadrivalent flu vaccines for all populations globally.

Sanofi is a committed public health partner providing life-saving vaccines and immunizations for Canadians and people worldwide. As a global leader in influenza vaccine development and manufacturing, we have met increasing demand for doses of both Fluzone Standard-Dose and High-Dose vaccines over the past 4 years. Our footprint in Canada continues to grow with two new vaccine manufacturing facilities in Toronto. This includes the countrys largest pediatric and booster vaccine manufacturing facility, now open, and a second facility that will produce Fluzone High-Dose.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve peoples lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

InCanada, we employ over 2,000 people. We invest 20% of our revenue annually in biopharma research (representing $1.2 billion CAD in R&D investment over the last decade) creating jobs, business, and opportunities throughout the country. We are also on track to deliver over $2 billion CAD in new infrastructure investments by 2028.

In 2024, we are celebrating 110 years of heritage dedicated to developing innovative health solutions for Canadians. What started as a small laboratory in May of 1914, recognized for having advanced some of the greatest contributions to public health, both nationally and globally, has evolved to become the largest biomanufacturing facility in Canada.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

_____________________

SOURCE SANOFI

Read more from the original source:

Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza - BioSpace

Hawaii Residents Weigh Timing For Flu Shots And COVID Vaccines – Evrim Aac

July 28, 2024

With the summer heat still lingering, discussions around flu shots and COVID-19 vaccinations are heating up too. As many people prepare for the changing seasons, health officials recommend proactive measures to stay protected against the flu, particularly as influenza viruses remain unpredictable.

The U.S. Centers for Disease Control and Prevention (CDC) has always emphasized the importance of flu vaccinations, advising that the ideal windows for receiving the flu shot are September and October. According to the CDC, it is important for most individuals to wait until then to ensure maximum protection as flu season peaks in winter. In fact, the agency has stated that "Flu vaccination in July and August is not recommended for most people." However, the CDC does recognize that there are special considerations for certain groups.

For example, pregnant women who are in their third trimester are encouraged to consider getting vaccinated during the summer months. This early vaccination helps protect newborns, who cannot receive a flu vaccine right away. Similarly, children who require two doses of the flu vaccine should receive the first dose as soon as it becomes available. The second dose must be given at least four weeks later, ensuring that they are adequately protected before flu season hits.

The backbone of flu vaccination recommendations is the recognition that building immunity earlier is crucial. For adults, especially those aged 65 and older, and pregnant women in the earlier trimesters, it's best to wait for the fall to get vaccinated unless they won't be able to return later. Taking vaccinations closer to the peak flu season means the protective effects of the vaccine will be at their strongest when flu viruses begin to circulate widely.

Nationwide, the threat of flu remains potent. The CDC reported that more than 44,900 people succumbed to flu complications during the lengthy 2023-2024 flu season. This grim statistic underscores the urgency of preparing for the upcoming flu season adequately.

In addition to flu vaccines, conversations about COVID-19 booster shots remain prevalent, especially as different variants continue to circulate. Many people have been reflecting on their vaccination statuses, prompting questions such as, "Is it wise to get the latest COVID-19 booster now or wait until the updated vaccine comes out this fall?" Health experts suggest that the decision could depend heavily on individual health circumstances.

The CDC advises that individuals who haven't been vaccinated against COVID-19 at all should consider getting the currently available vaccine as a safety measure. Furthermore, for those who have already been vaccinated but desire further protection due to rising case numbers, getting the existing booster is also an option. However, they may need to weigh this decision against potential delays in receiving the updated vaccine that emerges later in the fall.

Timing plays a significant role in vaccinations. The CDC noted that there is a general four-month interval recommended between COVID-19 doses. Notably, groups such as the elderly, those who are immunocompromised, and pregnant women, particularly in late pregnancy stages, may benefit from being vaccinated sooner rather than later.

While 2023's COVID-19 statistics are soberingover 75,500 people lost their liveswe continue to navigate vaccinations and preventative measures in an ongoing effort to manage the health landscape shaped by the pandemic. The overall takeaway? Its essential to stay informed about vaccination schedules and guidelines to safeguard personal health and the wellbeing of the community.

In the midst of health discussions, citizens have also raised clarifications regarding the voting process, particularly concerning mail-in ballots. Many people find themselves confused as to how the timeline operates for returning voted ballots.

An anxious voter reminded officials: "The voted ballot must be received by 7 p.m. on Election Day." This means that simply dropping the ballot in the mail that very day does not guarantee that the vote will be counted. As reiterated by the state Office of Elections and various local resources, voters are urged to ensure that their ballots reach the County Elections Division by the specified time.

Communication is essential; when elections roll around, people must be clear on deadlines and procedures to ensure their voices are heard. Its a community effort to boost participation in the democratic process, and every vote counts.

While some of these conversations may spark anxietywhether its about health or civic dutythe tight-knit Hawaiian community has shown an admirable resilience. Instances of encouragement, like young skateboarders supporting newcomers at local parks, highlight how kindness and support can help people navigate both personal and societal challenges.

By engaging with local events and supporting one another through shared experiences, Hawaiians can foster a spirit of community that extends beyond just health and voting. It's reminders like these that underscore the importance of empathy during times of uncertainty, be it through health measures or civic participation.

As summer wanes and fall approaches, health officials stress vigilance: not only in keeping up with vaccinations but also staying informed about electoral responsibilities. This dual focus on health and civic engagement prepares individuals and communities to face the flu season and participate effectively in democratic processes.

So as everyone gears up for the impending seasonal transitions, consider these aspects of wellness and responsibility. Whether youre contemplating a flu shot or wondering about voting deadlines, the essence lies in being proactive and taking informed steps toward securing health and ensuring participation.

Give Feedback. How was this article?

You can help us improve by leaving feedback specific to this content.

Which of the following feelings did this article evoke in you? Multiple Selection

How would you rate the quality of this article?

How easy was it for you to find the information you were looking for in this article?

Super Hard Super Easy

Artificial intelligence is increasingly used in content creation. What percentage of this article do you estimate was generated by AI?

How can we improve this article (or our articles in general)?

Do you have any other suggestions for improving our content or website?

Thanks for the feedback

Thank you for supporting us to improve ourselves with your feedback.

See the original post:

Hawaii Residents Weigh Timing For Flu Shots And COVID Vaccines - Evrim Aac

High-Dose Quadrivalent Vaccine Remains Preferentially Recommended to Protect Seniors in Canada – Precision Vaccinations

July 28, 2024

(Precision Vaccinations News)

As flu shots arrive in local pharmacies next month, Canadians will have different vaccines to choose which is best for their needs.

To assist this decision process, the Canadian National Advisory Committee on Immunizations (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 recommends FluzoneHigh-Dose Quadrivalent among the preferential influenza vaccines over standard-dose influenza vaccines.

According to NACI on July 26, 2024, FluzoneHigh-Dose Quadrivalent has the most substantial body of supporting evidence among preferentially recommended vaccines for adults 65 years of age and older.

Dr.Angel ChuMD, FRCPC,Infectious disease specialist, Clinical Assistant Professor,University of Calgary, STI Clinic Calgary, and Vice-Chair of Immunize Canada, commented in a press release,In the newest NACI statement, FluzoneHigh-Dose continues to be recommended for adults 65 years of age and older. NACI also recognizes FluzoneHigh-Dose has the most substantial body of supporting evidence among flu vaccines for seniors.

Influenza can cause mild to severe illness.Some populations, especially young children and adults 65 and older, are at a higher risk for serious influenza complications.

Sanofi says vaccination is the most effective way to prevent influenza and its complications.

Earlier this year, the WHOrecommendedthattrivalentvaccinesbe deployed duringthe 2024-2025 northern hemisphere influenza season.

On June 27, 2024, the U.S. Centers for Disease Control and Prevention vaccine committeemeeting included presentations focused on Considerationsand Proposed Recommendations for the 2024-25 Influenza Season in the United States. Physicians, nurses, andpharmacistscan offer patients up to nine different influenza vaccines for the2024 - 2025 flu season.

Go here to see the original:

High-Dose Quadrivalent Vaccine Remains Preferentially Recommended to Protect Seniors in Canada - Precision Vaccinations

Influenza and Flu – Anne Arundel County Department of Health

July 28, 2024

What is Influenza or Flu?

Influenza or flu is a viral infection of the nose, throat and lungs that can make anyone sick. It is not life-threatening in healthy individuals; however, older people, young children, pregnant women and those with chronic health problems are more likely to become seriously ill or be hospitalized.

Symptoms include fever, chills, fatigue, runny nose, cough, muscle aches and headaches.

Persons should consult with their medical provider before getting the seasonal flu shot if they:

The flu virus is contained in secretions from the nose and respiratory system of a person who has the flu. Viruses get in the air when the person sneezes or coughs. Covering a cough or sneeze with a tissue, mask or even a sleeve reduces the airborne virus. Flu viruses can also get on surfaces. When a person touches a surface contaminated with the flu virus and then touches their nose, mouth or mucus membranes, they can contract the flu.

General Prevention

Hand washingis one of the easiest and best ways to prevent infection and to avoid getting or passing on the flu virus. Use alcohol-based hand sanitizers if washing facilities are not handy. Teach children how to wash their hands properly.

The Centers for Disease Control and Prevention (CDC) and the American Society for Microbiology (ASM) offer these instructions for proper hand washing:

Flu season can begin as early as October and last as late as May. The Centers for Disease Control and Prevention (CDC) recommend that people get their seasonal flu vaccine as soon as vaccine becomes available in their community. Vaccination before December is best since this timing ensures that protective antibodies are in place before flu activity is typically at its highest.

People should get vaccinated every year. Even if the current flu vaccine protects against the same flu viruses as the previous years vaccine, immunity to flu viruses declines over time and may be too low to provide protection after a year.

Read the rest here:

Influenza and Flu - Anne Arundel County Department of Health

Study points to route for ‘one and done’ flu vaccine – pharmaphorum

July 28, 2024

Scientists in the US have developed a new universal form of influenza vaccine that they say could protect against all strains of the virus and do away with the annual scramble to match shots to circulating flu strains.

The team led by researchers at Oregon Health & Science University (OHSU) think their 'one and done' model which uses a cytomegalovirus (CMV) vector could confer lifetime immunity against the evolving virus.

While still in the animal testing stage, initial results published in Nature Communications have been promising against H5N1, a bird flu strain that is a frontrunner to cause a new pandemic.

In the past few years, a highly pathogenic strain of H5N1 has emerged that can jump between 50 animal species, raising the threat level, and leading the World Health Organization to suggest that the next pandemic is most likely to be caused by an influenza virus.

The OHSU team have demonstrated in non-human primates that their CyCMV/Flu candidates were able to protect animals from H5N1 even though the vaccines were based on a historic H1N1 strain of the virus that was responsible for the 1918 Spanish flu outbreak that killed millions of people worldwide.

In the study, six of 11 macaque monkeys inoculated with CyCMV/Flu survived after exposure to H5N1, which has a very high fatality rate. In contrast, a control group of six unvaccinated primates exposed to the H5N1 virus all died.

Jonah Sacha, head of pathobiology at the university's National Primate Research Center and one of the leaders of the programme, has suggested that it could be possible to develop the technology into a usable flu vaccine within the next five years.

That is partly because OHSU's CMV platform has already transitioned from the lab to clinical testing. The technology underpins a preventive HIV vaccine candidate developed by Vir Biotechnology, VIR-1388, that recently started phase 1 testing in the US and South Africa.

OHSU's method involves inserting small pieces of target pathogens into a weakened form of CMV, a virus that infects most people in their lifetimes and produces mild or no symptoms unless they are immunocompromised.

The virus acts as a vector specifically designed to induce an immune response from the body's T-cells, focusing on nucleoproteins found in the interior of the flu virus ( M1, NP, and PB1) that are less likely to mutate and evolve over time.

This approach differs from existing flu vaccines, which are designed to induce an antibody response that targets strains based on the arrangement of hemagglutinin (HA) and neuraminidase (NA) glycoproteins covering the exterior surface.

"It worked because the interior protein of the virus was so well preserved," said Sacha. "So much so that, even after almost 100 years of evolution, the virus can't change those critically important parts of itself."

And, according to the researchers, the same approach could be used for other pandemic viruses, including COVID-19.

"It's a very viable approach," said Sacha. "For viruses of pandemic potential, it's critical to have something like this. We set out to test influenza, but we don't know what's going to come next."

Other groups are also working on ways to deliver a universal flu vaccine.

One team at the National Institutes of Health (NIH) in the US is running a phase 1 trial of a 'mosaic' vaccine, based on a virus-like particle (VLP) that displays HA antigens in repeating patterns on self-assembling nanoparticle scaffolds. Another is testing an mRNA-based vaccine coding for the tail portion of the HA antigen, which is more conserved between strains.

Read more:

Study points to route for 'one and done' flu vaccine - pharmaphorum

Universal influenza vaccine could offer lifetime immunity – Earth.com

July 28, 2024

Just imagine, a world where vaccines must be administered only once for lifetime immunity. Well, thanks to groundbreaking research led by the Oregon Health & Science University (OHSU), were witnessing the dawn of a one and done vaccine promising lifetime protection against the ever-evolving influenza virus.

Dr. Jonah Sacha, a senior co-author of the study and head of the Division of Pathobiology at OHSUs Oregon National Primate Research Center (ONPRC), is the brain behind this research.

Its exciting because in most cases, this kind of basic science research advances the science very gradually; in 20 years, it might become something, said Dr. Sacha. This could actually become a vaccine in five years or less.

The problem with influenza is that its not just one virus, said Dr. Sacha. Like the SARS-CoV-2 virus, its always evolving the next variant and were always left to chase where the virus was, not where its going to be.

Study co-senior author Dr.Simon Barratt-Boyes, professor of infectious diseases, microbiology and immunology at Pitt, noted that the inhalation of aerosolized H5N1 influenza virus causes a cascade of events that can trigger respiratory failure.

The immunity induced by the vaccine was sufficient to limit virus infection and lung damage, protecting the monkeys from this very serious infection, said Dr. Barratt-Boyes.

The novelty lies in the unconventional approach used for the research. Instead of fighting the contemporary H5N1 virus, the experts immunized primates against the infamous influenza virus of 1918, the one that brought the world to its knees.

What did the researchers find? A robust immune response.

The experiment involved inoculating 11 nonhuman primates against the century-old nemesis, and exposing them to the deadly H5N1. Six of them lived, while the control group of six unvaccinated primates did not survive.

It worked because the interior protein of the virus was so well preserved, explained Dr. Sacha. So much so, that even after almost 100 years of evolution, the virus cant change those critically important parts of itself.

Traditional vaccines focus on the exterior surface proteins of viruses, which mutate faster than Usain Bolt runs. This often leaves us trying to hit a moving target. The wizards at OHSU took a different route. They focused on the internal structural proteins, which remain relatively stable over time.

This translates into a stationary target for our bodys T cells to destroy, regardless of whether the virus is an old nemesis or a new variant. Using a century-old template for their experiment and achieving success is a testament to this novel approach.

Dr. Sacha believes that the platform could be effective against other mutating viruses including SARS-CoV-2, the virus that causes COVID-19.

The same vaccine platform is currently being used in a clinical trial against HIV, another formidable virus. Moreover, a recent publication by the same scientists suggests possible applications in targeting specific cancer cells.

As this research progresses, there are numerous implications for public health and disease management. A universal influenza vaccine could significantly reduce the global burden of seasonal flu epidemics and pandemic outbreaks.

According to Dr. Sacha, a one-shot solution for influenza could be a reality in five to 10 years. We might be on the brink of a revolution in how we address infectious diseases.

The research was made possible thanks to support from the Bill & Melinda Gates Foundation Grand Challenges grant awards and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, among other contributors.

Its a massive sea change within our lifetimes, said Dr. Sacha. There is no question we are on the cusp of the next generation of how we address infectious disease.

This research isnt just about fighting influenza its about our journey toward a healthier future. Its about the evolution of medical science and our relentless pursuit of solutions.

And above all, its about hope for a world where one shot is all we need to stay safe from the ceaseless mutations of deadly viruses. Could the era of one and done vaccines be just around the corner? Only time will tell.

The study is published in the journalNature Communications.

Like what you read?Subscribe to our newsletterfor engaging articles, exclusive content, and the latest updates.

Check us out onEarthSnap, a free app brought to you byEric Rallsand Earth.com.

See original here:

Universal influenza vaccine could offer lifetime immunity - Earth.com

Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza – Canada…

July 28, 2024

TORONTO, July 26, 2024 /CNW/ - The National Advisory Committee on Immunization's (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 continues to recommend FluzoneHigh-Dose Quadrivalent among the preferential influenza vaccines, over standard dose influenza vaccines, to protect adults 65 years of age and older against influenza. According to NACI, Fluzone High-Dose Quadrivalent has the most substantial body of supporting evidence among preferentially recommended vaccines for adults 65 years of age and older.i

Delphine Lansac

General Manager, Vaccines Canada, Sanofi

"More than one out of two seniors in Canada who received a flu shot were immunized with FluzoneHigh-Dose this past flu season. FluzoneHigh-Dose has a longstanding and consistent body of clinical evidence supporting its benefits to protect adults 65 years and older from influenza and reduce the risk of its potentially severe complications. As a leader in public health protection in Canada, with roots dating back 110 years, we are proud to soon be manufacturing Fluzone High-Dose right here in Toronto."

Dr. Angel Chu MD, FRCPCInfectious disease specialist, Clinical Assistant Professor, University of Calgary, STI Clinic Calgary, and Vice-Chair of Immunize Canada

"In the newest NACI statement, Fluzone High-Dose continues to be recommended for adults 65 years of age and older. NACI also recognizes Fluzone High-Dose has the most substantial body of supporting evidence among flu vaccines for seniors."

Influenza can cause mild to severe illness, including approximately 12,000 hospitalizations and 3,500 deaths annually in Canadaii. Some populations, especially young children and adults 65 years of age and older, are at a higher risk for serious influenza complicationsiii. Vaccination is the most effective way to prevent influenza and its complicationsiv.

Fluzone High-Dose Quadrivalent Influenza Vaccine is specifically designed to provide protection for adults 65 years of age and older with 4 times the active component dosage of a standard vaccine. To date, Fluzone High-Dose is available in more than 20 countries including the US, Canada, and Germany and continues to be publicly funded in Canada by numerous provinces and territories.

Fluzone High-Dose Quadrivalent Influenza Vaccine will transition to a trivalent formulation for the 2025-2026 influenza season. The timing of this transition is also in line with the recommendation of European health authorities. This is following the direction of the World Health Organization to exclude the B/Yamagata lineage from influenza vaccine formulations due to the absence of confirmed detection of naturally occurring B/Yamagata lineage viruses since March 2020. The benefits of annual influenza vaccination remain unchanged, whether trivalent or quadrivalent. There are no safety issues associated with the continued use of quadrivalent flu vaccines for all populations globally.

Sanofi is a committed public health partner providing life-saving vaccines and immunizations for Canadians and people worldwide. As a global leader in influenza vaccine development and manufacturing, we have met increasing demandfor doses ofboth FluzoneStandard-Dose and High-Dose vaccinesover the past 4 years. Ourfootprint in Canada continues to grow with two new vaccine manufacturing facilities in Toronto. This includes the country's largest pediatric and booster vaccine manufacturing facility, now open, and a second facility that will produce FluzoneHigh-Dose.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

InCanada, we employ over 2,000 people. We invest 20% of our revenue annually in biopharma research (representing $1.2 billion CAD in R&D investment over the last decade) creating jobs, business, and opportunities throughout the country. We are also ontrack to deliver over $2 billion CAD in new infrastructure investments by 2028.

In 2024, we are celebrating 110 years of heritage dedicated to developing innovative health solutions for Canadians. What started as a small laboratory in May of 1914, recognized for having advanced some of the greatest contributions to public health, both nationally and globally, has evolved to become the largest biomanufacturing facility in Canada.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

_____________________

SOURCE SANOFI

For more information and media inquiries, please contact: Alana Vineberg, +1 416-529-1654, [emailprotected]

More here:

Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza - Canada...

Bird flu isnt spreading in humans for now. But there are vaccines in the pipeline if that changes – The Conversation Indonesia

July 18, 2024

Since May, a number of poultry farms around Australia have faced outbreaks of avian influenza, or bird flu. These outbreaks have been devastating for the poultry farms affected, necessitating large-scale culls, and have caused knock-on effects for the countrys egg supplies.

The poultry farm outbreaks have been linked to bird flu strains beginning with H7 (such as H7N3 and H7N8). But the strain causing most concern at present is arguably a different strain H5N1.

This strain is spreading rapidly around the world, and can cause more serious illness and death in poultry, birds and mammals.

Experts are warning H5N1 could soon reach Australia. And while bird flu isnt currently spreading between humans, this could change in the future.

So where are we at with vaccines for bird flu?

H5N1 first emerged in southern China in 1996.

Strains like H5N1 are further broken down into variants called clades. Since emerging in 2020, clade 2.3.4.4b has spread around the world, giving experts cause for concern. Recently, it has been causing outbreaks not only in wild birds and poultry, but also in dairy cows, notably in the United States.

While H5N1 is yet to be detected in birds or other wildlife in Australia, as it continues to spread in other regions, there are concerns were likely to see it here soon. CSIRO experts have this week warned the risk of H5N1 being imported is higher this year compared with previous years.

Fortunately, cases in humans remain rare. Five human cases of H5N1 clade 2.3.4.4b have been reported in the US since 2022, all of whom had close contact with dairy cows or poultry, and around ten others elsewhere in the world.

There was a single imported human case of H5N1 in Australia in a child who returned from overseas earlier this year, but of a different clade.

One of the biggest challenges with influenza viruses is that they can change fairly easily. Theres a possibility that some of these changes may give the virus the ability to transmit more readily from person to person. This could lead to widespread transmission worldwide, or a pandemic.

Given H5N1 viruses have been around for a while, we actually already have a few vaccines designed to protect against this bird flu strain in the event of sustained transmission in humans. The US approved one from Sanofi Pasteur back in 2007, the European Union approved one from GSK in 2008, and Australia approved one from CSL Limited in the same year.

Older H5N1 vaccines were traditional egg-based vaccines, which work by growing the virus in fertilised chicken eggs and deactivating it, then injecting it into the muscle so our immune system can be trained to respond.

More recently, CSL Seqirus has created a cell-based H5N1 vaccine. This shot is based on technology already used to manufacture their seasonal flu vaccines, where the virus is grown in cultured cells of mammalian origin (rather than in eggs). Developing a vaccine that doesnt require chicken eggs to make is sensible in the context of bird flu, which can limit the availability of eggs.

While the risk in humans remains low, the World Health Organization has suggested humans dont need to be vaccinated against bird flu at this stage.

That said, Finland plans to roll the CSL Seqirus shots out imminently to those at highest risk (people routinely exposed to animals who may be infected), making them the first country to vaccinate against H5N1.

While research has suggested existing vaccines produce immune responses that will provide sufficient protection against the currently circulating strains, vaccines based on older versions of H5N1, or even those made more recently, may not be an ideal match for future strains of bird flu.

mRNA vaccine technology is now well established for COVID, while an mRNA vaccine against RSV (respiratory syncytial virus) was recently approved in the US.

mRNA (messenger RNA) vaccines essentially work by giving our immune system instructions to make proteins, usually bits found on the surface of viruses. Our immune system then recognises and responds to these proteins to protect us if we encounter the virus.

This technology also offers promise for bird flu vaccines. Moderna began clinical trials for mRNA vaccines against both H5 and H7 strains in 2023 and recently secured funding to continue late-stage development. Other companies including GSK and Pfizer are also working on mRNA vaccines against H5N1.

One of the benefits of this technology is that if the virus changes significantly from the version circulating at a given time, mRNA vaccines can be adapted to these changes quite quickly.

Other approaches are also being investigated, including universal flu vaccines that could protect from all types of flu. But these are unlikely to be available soon.

Being a virus primarily of birds, another strategy is to vaccinate the birds themselves. In some countries where bird flu is consistently found in birds such as Egypt and China, vaccinating poultry in particular has been routine for some time.

With the ever-increasing global spread of H5N1 and the growing number of species infected, there are concerns about the potential for this strain to cause a pandemic.

If we were to see a bird flu pandemic, fortunately we are perhaps in a better position than ever before to respond. Not only have we learnt a lot in recent years from responses to other infectious diseases, particularly COVID, but technology and capacity to be able to make vaccines rapidly has also come a long way.

Read more here:

Bird flu isnt spreading in humans for now. But there are vaccines in the pipeline if that changes - The Conversation Indonesia

Finland is offering farmworkers bird flu shots. Some experts say the U.S. should, too. – Minnesota Reformer

July 18, 2024

Reprinted with permission from KFF Health News.

As bird flu spreads among dairy cattle in the U.S., veterinarians and researchers have taken note of Finlands move to vaccinate farmworkers at risk of infection. They wonder why their government doesnt do the same.

Farmworkers, veterinarians, and producers are handling large volumes of milk that can contain high levels of bird flu virus, said Kay Russo, a livestock and poultry veterinarian in Fort Collins, Colorado. If a vaccine seems to provide some immunity, I think it should be offered to them.

Among a dozen virology and outbreak experts interviewed by KFF Health News, most agree with Russo. They said people who work with dairy cows should be offered vaccination for a disease that has killed roughly half of the people known to have gotten it globally over the past two decades, has killed cats in the U.S. this year, and has pandemic potential.

However, some researchers sided with the Centers for Disease Control and Prevention in recommending against vaccination for now. Theres no evidence that this years bird flu virus spreads between people or causes serious disease in humans. And its unclear how well the available vaccine would prevent either scenario.

But the wait-and-see approach is a gamble, said Jennifer Nuzzo, director of the Pandemic Center at Brown University. By the time we see severe outcomes, it means a lot of people have been infected.

Now is the time to offer the vaccines to farmworkers in the United States, said Nahid Bhadelia, director of the Boston University Center on Emerging Infectious Diseases. Even more urgent measures are lagging in the U.S., she added. Testing of farmworkers and cows is sorely needed to detect the H5N1 bird flu virus, study it, and extinguish it before it becomes a fixture on farms posing an ever-present pandemic threat.

Demetre Daskalakis, director of the CDCs National Center for Immunization and Respiratory Diseases, said the agency takes bird flu seriously, and the U.S. is stockpiling 4.8 million doses of the vaccine. But, he said, theres no recommendation to launch a vaccine campaign.

Its all about risk-benefit ratios, Daskalakis said. The benefits are blurry because there hasnt been enough testing to understand how easily the virus jumps from cows into people, and how sick they become. Just four people in the United States have tested positive this year, with mild cases too few to draw conclusions.

Other farmworkers and veterinarians working on dairy farms with outbreaks have reported being sick, Russo said, but they havent been tested. Public health labs have tested only about 50 people for the bird flu since the outbreak was detected in March.

Still, Daskalakis said the CDC is not concerned that the agency is missing worrisome bird flu infections because of its influenza surveillance system. Hospitals report patients with severe cases of flu, and numbers are normal this year.

Another signal that puts the agency at ease is that the virus doesnt yet have mutations that allow it to spread rapidly between people as they sneeze and breathe. If we start to see changes in the virus, thats another factor that would be part of the decision to move from a planning phase into an operational one, Daskalakis said.

On July 8, researchers reported that the virus may be closer to spreading between people than previously thought. It still doesnt appear to do so, but experiments suggest it has the ability to infect human airways. It also spread between two laboratory ferrets through the air.

In considering vaccines, the agency takes a cue from a 1976 outbreak of the swine flu. Officials initially feared a repeat of the 1918 swine flu pandemic that killed roughly half a million people in the United States. So they rapidly vaccinated nearly 43 million people in the country within a year.

But swine flu cases turned out to be mild that year. This made the vaccine seem unnecessarily risky as several reports of a potentially deadly disorder, Guillain-Barr Syndrome, emerged. Roughly one of every million people who get influenza vaccines may acquire the disorder, according to the CDC. That risk is outweighed by the benefits of prevention. Since Oct. 1, as many as 830,000 people have been hospitalized for the seasonal flu and 25,000 to 75,000 people have died.

An after-action report on the 1976 swine flu situation called it a sobering, cautionary tale about responding prematurely to an uncertain public health threat. Its a story about what happens when you launch a vaccine program where you are accepting risk without any benefit, Daskalakis said.

Paul Offit, a virologist at the Childrens Hospital of Philadelphia, sides with the CDC. Id wait for more data, he said.

However, other researchers say this isnt comparable to 1976 because they arent suggesting that the U.S. vaccinate tens of millions of people. Rather theyre talking about a voluntary vaccine for thousands of people in close contact with livestock. This lessens the chance of rare adverse effects.

The bird flu vaccine on hand, made by the flu vaccine company CSL Seqirus, was authorized last year by the European equivalent of the FDA. An older variety has FDA approval, but the newer variety hasnt gotten the green light yet.

Although the vaccine targets a different bird flu strain than the H5N1 virus now circulating in cows, studies show it triggers an immune response against both varieties. Its considered safe because it uses the same egg-based vaccine technology deployed every year in seasonal flu vaccines.

For these reasons, the United States, the United Kingdom, the Netherlands, and about a dozen other countries are stockpiling millions of doses. Finland expects to offer them to people who work on fur farms this month as a precaution because its mink and fox farms were hit by the bird flu last year.

In contrast, mRNA vaccines being developed against the bird flu would be a first for influenza. On July 2, the U.S. government announced that it would pay Moderna $176 million for their development, and that the vaccines may enter clinical trials next year. Used widely against covid-19, this newer technology uses mRNA to teach the immune system how to recognize particular viruses.

In the meantime, Florian Krammer, a flu virologist at Mount Sinais Icahn School of Medicine, said people who work on dairy farms should have the option to get the egg-based vaccine. It elicits an immune response against a primary component of the H5N1 bird flu virus that should confer a degree of protection against infection and serious sickness, he said.

Still, its protection wouldnt be 100%. And no one knows how many cases and hospitalizations it would prevent since it hasnt been used to combat this years virus. Such data should be collected in studies that track the outcomes of people who opt to get one, he said.

Krammer isnt assuaged by the lack of severe bird flu cases spotted in clinics. If you see a signal in hospitals, the cat is out of the bag. Game over, we have a pandemic, he said. Thats what we want to avoid.

He and others stressed that the United States should be doing everything it can to curb infections before flu season starts in October. The vaccine could provide an additional layer of protection on top of testing, wearing gloves, and goggles, and disinfecting milking equipment. Scientists worry that if people get the bird flu and the seasonal flu simultaneously, bird flu viruses could snag adaptations from seasonal viruses that allow them to spread swiftly among humans.

They also note it could take months to distribute the vaccines after theyre recommended since it requires outreach. People who work beside dairy cows still lack information on the virus, four months into this outbreak, said Bethany Boggess Alcauter, director of research at the National Center for Farmworker Health.

Health officials have talked with dairy farm owners, but Boggess interviews with farmworkers suggest those conversations havent trickled down to their staff. One farmworker in the Texas Panhandle told her he was directed to disinfect his hands and boots to protect cows from diseases that workers may carry. They never told us if the cow could infect us with some illness, the farmworker said in Spanish.

The slow pace of educational outreach is a reminder that everything takes time, including vaccine decisions. When deciding whether to recommend vaccines, the CDC typically seeks guidance from its Advisory Committee on Immunization Practices, or the ACIP. A consultant to the group, infectious disease researcher William Schaffner, has repeatedly asked the agency to present its thinking on Seqirus bird flu vaccine.

Rather than fret about the 1976 swine flu situation, Schaffner suggested the CDC consider the 2009-10 swine flu pandemic. It caused more than 274,000 hospitalizations and 12,000 deaths in the U.S. within a year. By the time vaccines were rolled out, he said, much of the damage had been done.

The time to discuss this with ACIP is now, said Schaffner, before the bird flu becomes a public health emergency. We dont want to discuss this until the cows come home in the middle of a crisis.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFFan independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News free Morning Briefing.

Continue reading here:

Finland is offering farmworkers bird flu shots. Some experts say the U.S. should, too. - Minnesota Reformer

Finland Is Offering Farmworkers Bird Flu Shots. Should the US Be Following Suit? – Truthout

July 18, 2024

As bird flu spreads among dairy cattle in the U.S., veterinarians and researchers have taken note of Finlands move to vaccinate farmworkers at risk of infection. They wonder why their government doesnt do the same.

Farmworkers, veterinarians, and producers are handling large volumes of milk that can contain high levels of bird flu virus, said Kay Russo, a livestock and poultry veterinarian in Fort Collins, Colorado. If a vaccine seems to provide some immunity, I think it should be offered to them.

Among a dozen virology and outbreak experts interviewed by KFF Health News, most agree with Russo. They said people who work with dairy cows should be offered vaccination for a disease that has killed roughly half of the people known to have gotten it globally over the past two decades, has killed cats in the U.S. this year, and has pandemic potential.

However, some researchers sided with the Centers for Disease Control and Prevention in recommending against vaccination for now. Theres no evidence that this years bird flu virus spreads between people or causes serious disease in humans. And its unclear how well the available vaccine would prevent either scenario.

But the wait-and-see approach is a gamble, said Jennifer Nuzzo, director of the Pandemic Center at Brown University. By the time we see severe outcomes, it means a lot of people have been infected.

This unsustainable food system must be reformed before it is too late, one advocate said.

Now is the time to offer the vaccines to farmworkers in the United States, said Nahid Bhadelia, director of the Boston University Center on Emerging Infectious Diseases. Even more urgent measures are lagging in the U.S., she added. Testing of farmworkers and cows is sorely needed to detect the H5N1 bird flu virus, study it, and extinguish it before it becomes a fixture on farms posing an ever-present pandemic threat.

Demetre Daskalakis, director of the CDCs National Center for Immunization and Respiratory Diseases, said the agency takes bird flu seriously, and the U.S. is stockpiling 4.8 million doses of the vaccine. But, he said, theres no recommendation to launch a vaccine campaign.

Its all about risk-benefit ratios, Daskalakis said. The benefits are blurry because there hasnt been enough testing to understand how easily the virus jumps from cows into people, and how sick they become. Just four people in the United States have tested positive this year, with mild cases too few to draw conclusions.

Other farmworkers and veterinarians working on dairy farms with outbreaks have reported being sick, Russo said, but they havent been tested. Public health labs have tested only about 50 people for the bird flu since the outbreak was detected in March.

Still, Daskalakis said the CDC is not concerned that the agency is missing worrisome bird flu infections because of its influenza surveillance system. Hospitals report patients with severe cases of flu, and numbers are normal this year.

Another signal that puts the agency at ease is that the virus doesnt yet have mutations that allow it to spread rapidly between people as they sneeze and breathe. If we start to see changes in the virus, thats another factor that would be part of the decision to move from a planning phase into an operational one, Daskalakis said.

On July 8, researchers reported that the virus may be closer to spreading between people than previously thought. It still doesnt appear to do so, but experiments suggest it has the ability to infect human airways. It also spread between two laboratory ferrets through the air.

In considering vaccines, the agency takes a cue from a 1976 outbreak of the swine flu. Officials initially feared a repeat of the 1918 swine flu pandemic that killed roughly half a million people in the United States. So they rapidly vaccinated nearly 43 million people in the country within a year.

But swine flu cases turned out to be mild that year. This made the vaccine seem unnecessarily risky as several reports of a potentially deadly disorder, Guillain-Barr Syndrome, emerged. Roughly one of every million people who get influenza vaccines may acquire the disorder, according to the CDC. That risk is outweighed by the benefits of prevention. Since Oct. 1, as many as 830,000 people have been hospitalized for the seasonal flu and 25,000 to 75,000 people have died.

An after-action report on the 1976 swine flu situation called it a sobering, cautionary tale about responding prematurely to an uncertain public health threat. Its a story about what happens when you launch a vaccine program where you are accepting risk without any benefit, Daskalakis said.

Paul Offit, a virologist at the Childrens Hospital of Philadelphia, sides with the CDC. Id wait for more data, he said.

However, other researchers say this isnt comparable to 1976 because they arent suggesting that the U.S. vaccinate tens of millions of people. Rather theyre talking about a voluntary vaccine for thousands of people in close contact with livestock. This lessens the chance of rare adverse effects.

The bird flu vaccine on hand, made by the flu vaccine company CSL Seqirus, was authorized last year by the European equivalent of the FDA. An older variety has FDA approval, but the newer variety hasnt gotten the green light yet.

Although the vaccine targets a different bird flu strain than the H5N1 virus now circulating in cows, studies show it triggers an immune response against both varieties. Its considered safe because it uses the same egg-based vaccine technology deployed every year in seasonal flu vaccines.

For these reasons, the United States, the United Kingdom, the Netherlands, and about a dozen other countries are stockpiling millions of doses. Finland expects to offer them to people who work on fur farms this month as a precaution because its mink and fox farms were hit by the bird flu last year.

In contrast, mRNA vaccines being developed against the bird flu would be a first for influenza. On July 2, the U.S. government announced that it would pay Moderna $176 million for their development, and that the vaccines may enter clinical trials next year. Used widely against COVID-19, this newer technology uses mRNA to teach the immune system how to recognize particular viruses.

In the meantime, Florian Krammer, a flu virologist at Mount Sinais Icahn School of Medicine, said people who work on dairy farms should have the option to get the egg-based vaccine. It elicits an immune response against a primary component of the H5N1 bird flu virus that should confer a degree of protection against infection and serious sickness, he said.

Still, its protection wouldnt be 100%. And no one knows how many cases and hospitalizations it would prevent since it hasnt been used to combat this years virus. Such data should be collected in studies that track the outcomes of people who opt to get one, he said.

Krammer isnt assuaged by the lack of severe bird flu cases spotted in clinics. If you see a signal in hospitals, the cat is out of the bag. Game over, we have a pandemic, he said. Thats what we want to avoid.

He and others stressed that the United States should be doing everything it can to curb infections before flu season starts in October. The vaccine could provide an additional layer of protection on top of testing, wearing gloves, and goggles, and disinfecting milking equipment. Scientists worry that if people get the bird flu and the seasonal flu simultaneously, bird flu viruses could snag adaptations from seasonal viruses that allow them to spread swiftly among humans.

They also note it could take months to distribute the vaccines after theyre recommended since it requires outreach. People who work beside dairy cows still lack information on the virus, four months into this outbreak, said Bethany Boggess Alcauter, director of research at the National Center for Farmworker Health.

Health officials have talked with dairy farm owners, but Boggess interviews with farmworkers suggest those conversations havent trickled down to their staff. One farmworker in the Texas Panhandle told her he was directed to disinfect his hands and boots to protect cows from diseases that workers may carry. They never told us if the cow could infect us with some illness, the farmworker said in Spanish.

The slow pace of educational outreach is a reminder that everything takes time, including vaccine decisions. When deciding whether to recommend vaccines, the CDC typically seeks guidance from its Advisory Committee on Immunization Practices, or the ACIP. A consultant to the group, infectious disease researcher William Schaffner, has repeatedly asked the agency to present its thinking on Seqirus bird flu vaccine.

Rather than fret about the 1976 swine flu situation, Schaffner suggested the CDC consider the 2009-10 swine flu pandemic. It caused more than 274,000 hospitalizations and 12,000 deaths in the U.S. within a year. By the time vaccines were rolled out, he said, much of the damage had been done.

The time to discuss this with ACIP is now, said Schaffner, before the bird flu becomes a public health emergency. We dont want to discuss this until the cows come home in the middle of a crisis.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF an independent source of health policy research, polling, and journalism. Learn more about KFF.

Truthout has launched a necessary fundraising campaign to support our work. Can you support us right now?

Each day, our team is reporting deeply on complex political issues: revealing wrongdoing in our so-called justice system, tracking global attacks on human rights, unmasking the money behind right-wing movements, and more. Your tax-deductible donation at this time is critical, allowing us to do this core journalistic work.

As we face increasing political scrutiny and censorship for our reporting, Truthout relies heavily on individual donations at this time. Please give today if you can.

Go here to see the original:

Finland Is Offering Farmworkers Bird Flu Shots. Should the US Be Following Suit? - Truthout

Page 3«..2345..1020..»